AIMD$0.6157-0.69%
Ainos, Inc.
Sector: Computer Peripheral Equipment, NECIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$4.55M
Float & O/S:
Inst Own:
DilutionScan read 51 of Ainos, Inc.'s SEC filings and found 6 warrant series, 2 convertibles, 1 ATM program, 2 shelf registrations and 1 completed offering on file for AIMD. The latest dilution event on file is ATM sales on Jul 24, 2026. Analysis updated Oct 16, 2026.
Signal8 Summary
AIMD
Reverse split and tight cash runway
Snapshot
Ainos is a distressed micro-cap transitioning from biotech to AI hardware. While FY 2025 revenue grew 499% to $124K, Q1 2026 revenue collapsed to just $161, showing the business is not yet generating sustainable sales.
What's Happening Right Now
- : Ainos launched a Smell AI study with National Taiwan University Hospital to use its AI Nose platform for emergency department overcrowding and infection risk monitoring.
- : Revenue collapsed to $161 in Q1 2026 from $106K a year ago as the company shifts focus from healthcare to industrial AI deployments, though operating expenses fell 30%.
- : The company secured a $2.8M loan from related party ASE Test at 2.5% interest, due in one year, to support operations.
